⚑ HITL study. AI-assembled by the RI agent team, grounded in FDA/partner-agency and peer-reviewed sources — every claim cited [n]. Read the verify-flags first:
FDA.gov pages blocked automated fetch — FDA's own wording (review types, the "under Project Orbis" dab+tram sentence) is carried through partner-agency primary pages (MHRA/HSA/Health Canada/TGA) + peer-reviewed sources; confirm verbatim on FDA.gov before external use.⚑
Correction to our own materials: Project ORBIS has only Types A / B / C — there is no "Type F." Any earlier reference (incl. a draft that listed "A/B/C/F") must be dropped. The "written-only" concept = Type C.⚑
Cumulative program totals (e.g., 521/633 applications) are secondary aggregations; the Lancet Oncology 2024 access figures came via summaries — confirm against the original.⚑
The Fore-relevance section is analysis/inference, not agency-stated fact, and uses the SME-corrected plixorafenib framing (RECIST, 6/9), not a bare "67%."
How Project ORBIS works RI-03 · FDA/OCE lens
FDA Oncology Center of Excellence (OCE) framework for concurrent submission & collaborative review of oncology products across partner regulators — launched May 2019. [1][2]
Review types (the whole model — A/B/C only)
Type
When the partner filing lands
What it enables
Type A · "Regular"
Concurrent / within ~30 days of the FDA submission
Concurrent review and possible concurrent action (near-simultaneous approvals). [2][3]
Type B · "Modified"
>30 days after FDA filing
Concurrent review, but no concurrent action — FDA typically decides first. [2][3]
Type C · "Written report only"
After FDA has already acted (positively)
FDA shares its completed review; partner does a reliance-style assessment. No concurrent review/action. [2][3]
Partners, eligibility & mechanics · RI-04
8 agencies: FDA (coordinator) + Australia (TGA) & Canada (Health Canada) — founding 2019 — plus Singapore (HSA) & Switzerland (Swissmedic) (2019–20), Brazil (ANVISA) (2020), UK (MHRA) (post-Brexit, Jan 2021), Israel (MoH) (~2021). EMA = observer only; PMDA not a formal member.⚑ [3][4]
Opt-in, case-by-case — FDA proposes high-impact oncology applications; each partner chooses whether to join a given review. Not every drug or partner participates. [4]
Eligibility: oncology product; FDA is a reviewing agency; generally expected to meet FDA priority-review criteria. [2]
Each agency stays sovereign — independent, non-binding decision under its own law/timeline; a separate local dossier is still required. ORBIS coordinates *review*, it is not a single filing or a unified approval. [3][4]
Precedents & outcomes RI-05 · precedent analysis
Precedent
What it shows
First ORBIS action Sep 2019
Lenvatinib + pembrolizumab (endometrial), FDA/TGA/Health Canada near-simultaneous; ~3 months ahead of the FDA goal date. [5]
Program scale 2019–2023
81 of 244 (33%) FDA oncology approvals went through ORBIS; 58% NMEs, 42% new-indication supplements. [6]
Dab + trametinib peds BRAF-V600E LGG KEY
Reviewed under Project ORBIS (FDA approval Mar 16 2023). The single most on-point precedent: a pediatric, CNS, BRAF-driven targeted therapy that used ORBIS.⚑ [7]
Tovorafenib R/R BRAF pLGG
Did NOT use ORBIS — domestic FDA accelerated approval (Apr 2024) + separate EMA route. The closest clinical comparator went the non-ORBIS path.⚑ [8]
Measured time benefit Swissmedic
Submission gap FDA→Swissmedic 168 → 33 days; review time 314 → 235.5 days (p=0.0002); FDA concordance 81% (ORBIS) vs 76%. [9]
The balanced case RI-06 · adversarial analyst
Pros / benefits
Faster multi-market access — median FDA→partner delay cut by ~135–175 days in measured cohorts. [9]
Single global dossier, parallel review — FDA-led assessment shared under reliance; less duplication. [3]
Net: ORBIS is a review-efficiency lever, not an access solution, for plixorafenib's pediatric BRAF-CNS / orphan path.
Upside: for a rare pediatric CNS indication, the partner markets Fore would otherwise reach slowly (AU/CA/CH/UK) each compress ~135–175 days of lag. Plixorafenib's Breakthrough / Fast Track / Orphan status fits ORBIS's "high-impact" selection. And the on-point precedent — dab+tram peds BRAF LGG used ORBIS — shows a pediatric BRAF-CNS drug can.
Central risk: a US filing built on accelerated approval + a small single-arm / response-rate basis (per the SME-corrected framing: RECIST, 6/9 evaluable — not a bare "67%") is exactly the profile partners & their HTA bodies have historically resisted. ORBIS does not de-risk that mapping.
HTA is the binding access gate and ORBIS does nothing for it — reimbursement (NICE/SMC/CADTH) still governs whether pediatric patients actually get the drug.
Priority partner markets (inference): UK (MHRA) & Australia (TGA) first; Canada (watch CADTH lag); Switzerland (best measured time savings). [9]
Bottom line (RI-01 synthesis): Project ORBIS would plausibly accelerate regulatory approval for plixorafenib in several partner markets and has a directly analogous pediatric-BRAF-CNS precedent (dab+tram). But it does not resolve the two things most likely to gate pediatric access — whether partners accept a US accelerated/surrogate basis, and separate HTA/reimbursement. Treat ORBIS as a targeted speed play for a defined partner set, decided alongside (not in place of) accelerated-approval and market-access strategy. Next: confirm the ⚑ items on FDA.gov and pull the paywalled Lancet/Swissmedic originals before this informs a filing decision.
References
FDA Oncology Center of Excellence — Project Orbis program page & FAQ (blocked to automated fetch; reference of record). fda.gov/about-fda/oncology-center-excellence/project-orbis
FDA / OCE — "Project Orbis: Global Collaborative Review Program," Clin Cancer Res 2020;26(24):6412; FDA Grand Rounds (2021); ASCO Post OCE interview (Dec 2020).
UK MHRA / GOV.UK — Guidance on Project Orbis (review types A/B/C, mechanics). gov.uk/guidance/guidance-on-project-orbis
Singapore HSA & Health Canada — Project Orbis pages (opt-in model, independence, local dossier). hsa.gov.sg; canada.ca/health-canada.
ASCO Post / AACR — first Orbis action, lenvatinib + pembrolizumab (endometrial), Sep 2019.
Cherla A, et al. — Orbis clinical benefit, reimbursement & prices (USA/Canada/England/Scotland), Lancet Oncol 2024 (via summaries — confirm original).
FDA — dabrafenib + trametinib, pediatric BRAF-V600E LGG, 16 Mar 2023, "conducted under Project Orbis" (fda.gov, blocked to fetch; corroborated ASCO Post/ONS/OncLive).
FDA Approval Summary — tovorafenib (Ojemda), Clin Cancer Res/PMID 39808502 — no Orbis mention.